Rankings
▼
Calendar
AQST Q3 2021 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
AQST
Aquestive Therapeutics, Inc.
$427M
Q3 2021 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$13M
+60.9% YoY
Gross Profit
$9M
66.9% margin
Operating Income
-$8M
-60.0% margin
Net Income
-$15M
-109.5% margin
EPS (Diluted)
$-0.37
QoQ Revenue Growth
-13.4%
Cash Flow
Operating Cash Flow
-$9M
Free Cash Flow
-$9M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$65M
Total Liabilities
$126M
Stockholders' Equity
-$60M
Cash & Equivalents
$31M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$13M
$8M
+60.9%
Gross Profit
$9M
$5M
+68.3%
Operating Income
-$8M
-$14M
+42.2%
Net Income
-$15M
-$17M
+12.1%
Revenue Segments
Manufacture and Supply Revenue
$10M
79%
Proprietary Product Sales
$2M
15%
Co-Development and Research Fees
$523,000
4%
License and Royalty Revenue
$328,000
2%
Geographic Segments
UNITED STATES
$11M
79%
Non-US
$3M
21%
← FY 2021
All Quarters
Q4 2021 →